INSIGHTS ON CLINICAL TRIAL TECHNOLOGIES

• The Scout Portal Helps Sites Hit SCRS'25 In 25 Goal

  Reducing site training time starts with intuitive tools. Aligning with SCRS’s 25 in 25 goal means eliminating complexity and empowering staff to focus on trial execution.

• Clinical Leader Smart Sourcing Solutions Expo: Suvoda eCOA, Unified With IRT On The Suvoda Platform

  Discover the unique advantages of Suvoda eCOA and IRT working together on a single, unified platform.

• Do We Still Need Patients In Tomorrow's Trials?

  Delve into how advanced technologies reshape drug development and patient care, and the crucial balance needed between innovation and ethical responsibility to achieve better trial outcomes.

• Creating Custom Listings Faster with AI

  Enable your Data Managers and Medical Monitors to create study-aware custom listings from natural-language requests while maintaining transparency and traceability.

• Qualified eSignature in Electronic Consent Systems

  2/25/2026

  This on‑demand session offers a clear, practical overview of the major eSignature types used in eConsent — ranging from simple electronic signatures to fully qualified electronic signatures — and explains when each is appropriate.

• Overview Of Central eSource From CRIO

  6/18/2025

  Central eSource transforms the conduct of clinical trials by replacing disparate, site-specific source templates with a unified, sponsor-designed framework.

• Clinical Leader Smart Sourcing Solutions Expo: Retention By Design

  9/9/2025

  Enhance participant retention through intuitive UX and real-time site support tools, while seamlessly integrating with IRT, EDC, and third-party platforms.

• Flexible Data Management For Growing Portfolio

  7/31/2025

  Explore strategic enhancements to a small biopharma's biometrics capabilities involving the deployment of 20 specialized professionals, which effectively bolstered the client’s organizational capacity.

• FDA's Vision On PRO Collection For RWE

  9/24/2024

  In this presentation, a distinguished panel of experts illuminates the crucial role of patient-reported outcomes (PROs) in shaping regulatory decisions and drug development strategies.